Brii Biosciences posts Phase 2 results for BRII-835/BRII-179 hepatitis B combo trial
Results were posted for a completed Phase 2 study testing BRII-835 (VIR-2218) alone or combined with BRII-179 (VBI-2601) in chronic hepatitis B patients.
Brii Biosciences, with collaborators Vir Biotechnology and VBI Vaccines, posted results for a completed Phase 2 trial in chronic hepatitis B infection.
- The trial, "NCT04749368," tested combination treatment of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection1 across three cohorts, with 91 participants enrolled1. The study was completed with an actual study completion date of 2023-07-041, and results were first posted on 2026-07-231.
- On the primary endpoint of sustained HBsAg loss after NRTI withdrawal, none of the participants in Cohort A, Cohort B, or Cohort C achieved sustained HBsAg loss1.
- Adverse events were reported in 10 of 10 participants in Cohort A, 37 in Cohort B, and 37 in Cohort C1, with serious adverse events occurring in 0 of 10 participants in Cohort A, 3 of 39 in Cohort B, and 6 of 41 in Cohort C1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.